DMD: Clinical Trials

2 recruiting. 2 Phase 3.

By phase and status

Phase	Trials	Status
Phase 3	2	Recruiting 2

Follow DMD: new trials by email Literature Review of DMD trials Research Report on DMD

Trials (filtered) newest first · largest first

All 2 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
A Phase 3 Study to Evaluate the Safety and Efficacy of AOC 1044 (Also Referred to as Delpacibart Zotadirsen) in Participants With DMD With Gene Mutations Amenable to Exon 44 Skipping AOC 1044, Placebo - Muscular Dystrophies, Muscular Dystrophies (Duchenne, Becker, Myotonic Dystrophy)	Phase 3	Recruiting	Avidity Biosciences, Inc.	70	2026-09-01	2026-10-13
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO) Zeleciment Rostudirsen (DYNE-251), Placebo - Duchenne Muscular Dystrophy (DMD), Muscular Dystrophy, Duchenne	Phase 3	Recruiting	Dyne Therapeutics	90	2026-06-01	2026-05-27

Narrower conditions

Genetic Diseases, Inborn (2)  ·  Muscular Dystrophies (2)  ·  Muscular Dystrophy, Duchenne (2)  ·  Myotonic Dystrophy (2)  ·  Neuromuscular Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, X-Linked (1)  ·  Infant, Newborn, Diseases (1)  ·  Muscular Diseases (1)  ·  Muscular Disorders, Atrophic (1)  ·  Musculoskeletal Diseases (1)  ·  Nervous System Diseases (1)

Broader conditions

Heredodegenerative Disorders, Nervous System (2)  ·  Myotonic Disorders (2)  ·  Neurodegenerative Diseases (2)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)  ·  Genetic Diseases, X-Linked (1)  ·  Muscular Diseases (1)  ·  Muscular Disorders, Atrophic (1)  ·  Musculoskeletal Diseases (1)  ·  Nervous System Diseases (1)

Sponsors

Avidity Biosciences, Inc. (1)  ·  Dyne Therapeutics (1)

Countries

Australia (1)  ·  Belgium (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  Spain (1)  ·  United Kingdom (1)  ·  United States (1)

NIH funding

2025 (1)